Claims systems must be able to manage bundled payments, David Nace, vice president, medical director, McKesson Health Solutions, told AHIP Institute attendees during his Thursday presentation.
Claims systems must be able to manage bundled payments, David Nace, vice president, medical director, McKesson Health Solutions, told AHIP Institute attendees during his Thursday presentation.
Like many healthcare issues, bundled payments are difficult to define. Nace outlined eight points that should be considered before adopting a bundled model:
Simplifying matters, Nace said the road to an effective program requires care management, episode initiation, episode resolution and financial and clinical analytics-all incorporating evidence-based medicine.
Nace recommends that organizations move through three phases to successfully create a bundled payment model.
“Look at how claims are triggered,” he said, “and then ensure that the claims system is on top of it. Finally, if the model is a fully bundled payment, who will receive the lump sum for services rendered?”
Be wary. There are always challenges attached, such as physician and hospital engagement, real-time data sharing, building scalability, quality assessment, price transparency and cost-sharing.
Bundled payments often come out in the same breath as accountable care organizations and patient-centered medical homes–both of which Nace said are compatible with the extended reimbursement system.
Bundled payments have been round since the 1980s. It started with diagnosis related groups covering the care incurred by a hospital and the Heart Bypass Center Demonstration in 1987 that assessed the feasibility and cost effectiveness of a negotiated, all-inclusive bundled payment arrangement for coronary artery bypass graft. That has led to the 2010 Senate Finance Committee’s expanded acute care episode model, including post-operative care, he said.
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More